Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18278350 | 0.82 | MAPT (0.46) | HTTLMNASMN1; SMN2CCNA2CDK2 | |
| SCHEMBL18278489 | 0.81 | CCNT1 (0.37) | HTTLMNASMN1; SMN2CCNA2CDK2 | |
| SCHEMBL18278091 | 0.80 | MAPT (0.44) | HTTLMNASMN1; SMN2CCNA2CDK2 | |
| SCHEMBL18278001 | 0.79 | HTT (0.40) | HTTLMNASMN1; SMN2CCNA2CDK2 | |
| SCHEMBL18278823 | 0.78 | MAPT (0.41) | HTTLMNASMN1; SMN2CCNA2CDK2 | |
| SCHEMBL18278929 | 0.77 | USP30 (0.45) | HTTLMNASMN1; SMN2CCNA2CDK2 | |
| SCHEMBL18278952 | 0.77 | MAPT (0.45) | SMN1; SMN2KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL18278737 | 0.76 | FLT3 (0.49) | CCNA2CDK2CDK9KDM4EKDR | |
| SCHEMBL18277877 | 0.76 | APP (0.46) | HTTLMNASMN1; SMN2CCNA2CDK2 | |
| SCHEMBL18277741 | 0.75 | JAK2 (0.39) | MAPTKDRFGFR1EPHB4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | claimed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | claimed |
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-06 | — | — | US | claimed |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-06 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | PMP22, MYT1, IKZF3 | HTT 313/4885LMNA 2906/4885SMN1; SMN2 32/4885 |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | HTT 313/4885LMNA 2906/4885SMN1; SMN2 32/4885 |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | PMP22, MYT1, IDE | HTT 998/4885LMNA 3490/4885SMN1; SMN2 119/4885 |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | HTT 313/4885LMNA 2906/4885SMN1; SMN2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.